Navigation Links
New discovery could lead to vaccines for plague and bacterial pneumonias
Date:1/25/2011

Saranac Lake, N.Y. There is an ongoing battle in the "war on terror" that remains mostly unseen to the public -- a race between scientists working to develop a vaccine to protect against plague and the terrorists who seek to use plague as a weapon.

"Governments remain concerned that bioweapons of aerosolized Yersinia pestis, the bacteria that causes plague, could kill thousands," said Stephen Smiley, a leading plague researcher and Trudeau Institute faculty member.

The anthrax scare that followed the terror attacks of September 11, 2001, made the threat of bioterrorism real and led to a surge in federal funding into research aimed at heading off such threats.

According to Dr. Smiley, there is no licensed plague vaccine in the United States. Together with postdoctoral associate Jr-Shiuan Lin, he is working to develop a vaccine that will protect members of the armed services and public from a "plague bomb."

Yersinia pestis is arguably the most deadly bacteria known to man. Plague infections of the lung, known as pneumonic plague, are extremely lethal. The bacteria, which grow both inside and outside the cells of the lung, usually lead to death within a week of infection.

Most of the plague vaccine candidates that have been studied aim to stimulate B cells to produce plague-fighting antibodies. However, animal studies suggest that antibodies may not be enough to protect humans from pneumonic plague. The Smiley laboratory has shown that T cells can also fight plague. The lab previously demonstrated that a single immunization with an experimental vaccine stimulates the production of T cells that provide partial protection against pneumonic plague.

New data, reported in the current issue of The Journal of Immunology, show that a second immunization, or booster, improves the protection provided by T cells. "It is particularly exciting that the boost seems to improve protection by increasing a newly described type of T cell, which we call a Th1-17 cell," said Dr. Smiley. These cells have characteristics of both Th1 cells, which defend against intracellular bacteria, and Th17 cells, which specialize at killing extracellular threats.

This research is focused primarily on thwarting the use of plague as a bioweapon. However, small, natural outbreaks of plague continue to this day. A plague vaccine will protect against both naturally occurring outbreaks and those that have been manufactured.

Additionally, Dr. Smiley believes these Th1-17 cells may be important in fighting other kinds of pneumonia: "Bacterial pneumonia is one of the most common causes of death in hospitals and, like plague, many of these pneumonias are caused by bacteria that grow both inside and outside the cells of our bodies."


'/>"/>

Contact: Brian Turner
bturner@trudeauinstitute.org
518-891-3080
Trudeau Institute
Source:Eurekalert  

Related medicine news :

1. UCSF Enters Drug Discovery Agreement with Genentech
2. UCSF enters drug discovery agreement with Genentech
3. New discovery: Plaice are spotted (on the inside)
4. SeqWright Advances Genomic Discovery With Isilon IQ
5. Effective prostate cancer treatment discovery
6. Co-Creator of Six Sigma Unveils “The Great Discovery” ... the 4th Generation of Six Sigma
7. U discovery gives insight into brain replay process
8. Discovery of cellular switch may provide new means of triggering cell death, treating disease
9. Discovery May Lead to Better Multiple Sclerosis Treatments
10. Astrogenetix Narrows in on MRSA Virulence Onboard Discovery
11. TGen Drug Development partners with Horizon Discovery for integrated personalized medicine service
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New discovery could lead to vaccines for plague and bacterial pneumonias
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec Solutions announced ... Foundation implement a Microsoft Dynamics GP solution that integrates to their PointClickCare EHR ... specializes in long-term care, Brooke Grove now has the capability to achieve its ...
(Date:4/28/2017)... ... April 28, 2017 , ... Semrock’s highly popular SearchLight Spectra ... modeling resource for fluorescence microscopists and optical system designers, enabling The Right Solution, ... spanning the globe, SearchLight has become a tremendously popular tool for the fluorescence ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... Healthcare companies ... But they will rapidly reject an outdated healthcare executive resume. , “If you’re a ... at your executive resume and wondering if it’s as ready as you are for ...
(Date:4/27/2017)... Reston, VA (PRWEB) , ... April 27, 2017 ... ... mobile application containerization, today announced an exhibitor sponsorship at MobileIron Live! 2017 ... leaders, and new technologies for an immersive, educational approach to helping organizations maximize ...
(Date:4/27/2017)... ... April 27, 2017 , ... Plastic Surgery Associates is excited to announce ... present at the upcoming Aesthetic Meeting. Held in San Diego, at the San Diego ... Canales will lend their expertise to the Premier Global Hot Topics session, speaking on ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  CVS Pharmacy, the retail division ... new store design to enhance the retail customer ... health-focused products and expanded beauty selections paired with ... discover new offerings. Together with its innovative digital ... the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
Breaking Medicine Technology: